A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study in Pediatric SMA Participants Previously Treated With Onasemnogene Abeparvovec (Zolgensma) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115
Latest Information Update: 22 May 2025
At a glance
- Drugs BIIB 115 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man
- Sponsors Biogen
Most Recent Events
- 22 Jan 2025 Planned End Date changed from 1 Sep 2027 to 19 Nov 2026.
- 22 Jan 2025 Planned primary completion date changed from 1 Sep 2027 to 19 Nov 2026.
- 22 Jan 2025 Status changed from recruiting to active, no longer recruiting.